검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tazemetostat |
Overview Company | Epizyme, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Lymphoma |
Overview Indication | Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting EZH2-mediated pathway |
MoA Biomarker | biomarkers of response, and exploring rational combinations with chemotherapy, targeted drugs, or immunothera |
PK/PD Half-life | 3.1 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Biological Evaluation of a Novel Compound with Predicted EZH2 and EED Binding Against Human Malignant Melanoma Cells.. Enhancer of Zeste Homolog 2 (EZH2), the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), mediates histone H3 lysine 27 trimethylation (H3K27me3), an epigenetic modification associated with transcriptional repression. EZH2 inhibitors (EZH2is) gained attention after the fi… |
Toxicology CRS | 7.1% |
Clinical Primary efficacy | ORR 76.5% |
Clinical ORR | 76.5% |
Clinical PFS | NA |
Clinical Result source | ClinicalTrials.gov NCT03456726 |
Clinical Data Tier / Score | A · 44 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tazemetostat |
Overview Company | Epizyme, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Lymphoma |
Overview Indication | Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting EZH2-mediated pathway |
MoA Biomarker | biomarkers of response, and exploring rational combinations with chemotherapy, targeted drugs, or immunothera |
PK/PD Half-life | 3.1 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Biological Evaluation of a Novel Compound with Predicted EZH2 and EED Binding Against Human Malignant Melanoma Cells.. Enhancer of Zeste Homolog 2 (EZH2), the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), mediates histone H3 lysine 27 trimethylation (H3K27me3), an epigenetic modification associated with transcriptional repression. EZH2 inhibitors (EZH2is) gained attention after the fi… |
Toxicology CRS | 7.1% |
Clinical Primary efficacy | ORR 76.5% |
Clinical ORR | 76.5% |
Clinical PFS | NA |
Clinical Result source | ClinicalTrials.gov NCT03456726 |
Clinical Data Tier / Score | A · 44 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교